Derek Gray (1950-2017): A Tribute


Derek Gray



Sir Peter J Morris pays tribute to one of Oxford’s outstanding academic surgeons who brought great renown to the department in the field of pancreatic islet transplantation.

In 1976 I was interviewing several applicants for the post of Senior House Officer on the new Renal Transplant Unit of the Nuffield Department of Surgery (NDS) to replace Chris Khoo, the first SHO. One of the applicants was Derek Gray, a graduate of Leeds University, who had worked with the internationally renowned Professor of Surgery at Leeds, John Goligher as a House Surgeon. Derek gave a good interview as I recollect already stating that he wished to pursue a career in academic surgery, but I think what really clinched the post for him was the reference from Professor John Goligher –

“Derek was a first-class medical student and I was fortunate to have him as my House Surgeon.  He was the most outstanding House Surgeon that I had ever had”.

Derek took up this post and everything that John Goligher had said about him proved to be true. He was outstanding in the Transplant Unit and I should point out that in those early days there was just the SHO and the Professor! During this time, he raised with me the question of whether the treatment of acute rejection might be done equally well with less problems with two or three high doses of intravenous methylprednisolone. The norm in those days was to massively increase the oral steroid dose and then taper it off over the next month or so. Needless to say, this was not without complications. In any case arguably the first randomised control trial in organ transplantation was carried out and directed by Derek Gray. It showed convincingly that rejection was reversed in most cases quite rapidly by intravenous methylprednisolone but what was striking was that the complication rate was halved compared to the standard treatment with continuing large doses of oral prednisolone. This was published in Lancet in 1977 with the intriguing title given to it by Derek “The big shot or not?” This attracted enormous interest and within the next few years the standard treatment of acute rejection became intravenous boluses of methylprednisolone.

Following his time as an SHO, although he had expressed the wish to pursue academic surgery, I felt he needed a good grounding in general surgery and sent him to Gloucester to work under Dr. Mike Gear and his team. This was a very successful move and Derek then came back to the NDS after two years in Gloucester very well trained in general surgery. He had been awarded an MRC Training Fellowship in the NDS to pursue research in the field of pancreatic islet transplantation as he had been impressed with the work of Danny Finch and John Garvey who were the first Research Fellows in the Pancreatic Islet Research Programme that I had established after arriving in Oxford in 1974.  Derek did some very innovative experimental research projects with pancreatic islets in the rodent but he was desperately interested in trying to isolate islets from the human pancreas which had not been achieved at that date except in very crude proportions. After nearly a year at work he was successful in producing an exceptionally pure isolation of human pancreatic islets, the first time that this had been achieved. A few years later the first human islet transplant was performed in Oxford, the culmination of Derek’s work over many years. The techniques that he had developed were rapidly adapted by the other few Units in the world working on human pancreatic islet transplantation and automated particularly by Camillo Ricordi and his colleagues. For this reason alone, Derek can be regarded as one of the pioneers of human pancreatic islet transplantation.

Following his three years as an MRC Training Fellow, his outstanding thesis on Pancreatic Islet Transplantation resulted in the award of a Doctorate of Philosophy (DPhil). He was then appointed as a Clinical Lecturer in the NDS with a special interest in vascular surgery and renal transplantation. Later he was promoted to a Readership in surgery and then to a Professorship of Experimental Surgery. He rapidly established his own Pancreatic Islet Research Laboratory which was incredibly productive over many years. Sadly, in his mid-40’s he developed Parkinson’s disease which presented in one arm but this gradually forced him to stop operating. However, he kept doing transplant outpatient clinics, ably assisted by his wife Annie who took his dictation for him for the notes. The patients loved this team effort as Derek had been very popular with them. His main activity remained the running of the Pancreatic Islet Research Laboratory until Paul Johnson took that over but Derek continued to contribute ideas and supervision. Derek served as a Councillor and later Secretary of the International Pancreatic and Islet Transplant Association (IPITA). In recent years IPITA established the Derek Gray Distinguished Travelling Scholarship Award as recognition of all his contributions to the field and the Association.

Derek was an original thinker as illustrated by his development of a theory for the biological role of the major histocompatibility complex molecules which he termed MHC based suppression. None of us, I have to say were enthusiastic about this concept, but that was not to say it was wrong. He also developed a computerised timetabling system for Medical School teaching which gave students the opportunity to feedback their opinion of their last teaching session. To this he added the concept of notional credits for teaching so that it was possible to reward those teachers who delivered excellence. This system is used in several Medical Schools outside the UK, but again was an illustration of his original thinking.

Derek was a Fellow of Oriel College and there he taught gross anatomy to first year medical students as well as introducing computer-driven projection of dissectible anatomy, comparing and contrasting that with radiological images.

All in all, Derek was one of the outstanding young people that I have had the privilege to work with and it is so sad that his academic surgical career but not his research career was brought to an untimely end by his Parkinson’s disease.

He leaves behind two sons, James and Robert. His wife, Annie, who was an enormous support to Derek, sadly died of pancreatic cancer some years ago.

Thus again, we say goodbye to one of the NDS’s outstanding academic surgeons who brought great renown to the NDS in the field of pancreatic islet transplantation.

Sir Peter J Morris AC, FRS

Behavioural Research Funding Call Launch

NHSBT recently launched a funding application call for Behavioural research; please see links below for your information.

Applications close on the 22nd September 2017

BRS Conference Online Survey


Dear Colleagues,

Thank you to everyone who attended the 2017 BRS Conference and to all who provided helpful feedback. This will be invaluable is helping us to plan future meetings.

In addition, we would like to get views about future meetings from a broad range of people across the UK renal community. I would therefore be very grateful if you would take 5 min to complete a short online survey (17 brief questions) to tell us your preferences. The BRS exists to serve the renal community and we would very much like to hear from you, so that we can be sure that we are responding to the needs of the community.

Please share this link with any colleagues who would be willing to complete the survey.

Your sincerely

Maarten Taal
BRS President
Prof M.W.Taal

Professor of Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham Honorary Consultant Nephrologist, Royal Derby Hospital

Kidney Research UK Educational Bursaries

Kidney Research UK is pleased to announce the availability of educational bursaries to support the dissemination of research into renal transplantation at European Society for Organ Transplantation (ESOT) Congress 2017.

For eligibility criteria and more details please follow this link: 

Closing date for applications 4 August 2017.

Alan Ting (1943-2017)


Alan Ting



Alan Ting who was one of a number of outstanding scientists in the field of histocompatibility and a prominent member of the BTS in the past died suddenly in April 2017.

Alan Ting was born in Sydney Australia and after schooling he undertook an Honours degree in Zoology graduating BSc Hons. in 1964. He then moved to Melbourne to the Blood Transfusion laboratory of the Royal Melbourne Hospital with a view to doing research for a Master’s degree.

However, in 1967 Peter Morris returned from the USA to the University Department of Surgery to join the new renal transplant programme with the aim of establishing tissue typing and transplant immunology laboratories. Alan Ting then joined Morris as his first PhD student. He completed his PhD in 1972. His thesis dealt with technical aspects of tissue typing as well as studies of antibodies in renal transplantation. One important contribution with Ian McKenzie, John Stocker and Peter Morris was the first description of cytotoxic antibodies in man against pig and sheep lymphocytes which would be a critical hurdle in any future attempts at xenotransplantation. He was also involved in several anthropological studies of HLA in New Guinea and South-East Asia.

He then went to UCLA to do a postdoc with Paul Terasaki from 1973-75. Meanwhile Morris had moved to Oxford in 1974 as Nuffield Professor of Surgery with the aim of establishing a transplant programme as well as a tissue typing and transplant immunology laboratories. Ting joined him as a senior research officer in 1975 and was to spend the next 15 years in Oxford in what was to prove an incredibly productive time, reflected by his 87 publications in that period. These ranged from unravelling the importance of the cross match to HLA studies in several diseases. His most important contributions were the recognition that highly sensitised patients awaiting transplantation often had autolymphocytoxins which allowed many such patients, who had been excluded from transplantation, to be transplanted successfully, and the demonstration that matching for the newly described HLA-DR was more important than matching for HLA -A,B. In the 1980s the BTS appointed him as one of the “3 wise men” (with Ross Taylor, a surgeon, and Douglas Briggs, a nephrologist) who were charged with visiting all renal transplant units in the UK to see if there was a ready explanation for the large discrepancy in one year graft survival between units.

Alan Ting had a remarkable career and was loved by all who worked with him. In the late 1980s he met the love of his life, Helena, soon to be his wife (they were married in San Francisco in 1990). As Helena was tied to California for family reasons Alan took a position at the California Pacific Medical Centre in 1990 as Director of the Histocompatibility Laboratory. In 1994, he moved to Stanford University as Associate Professor of Pathology and Co-Director of the Histocompatibility Laboratory; but was to move again in 2000 to Richmond, Virginia as Assistant Director and Director of Research at the United Network for Organ Sharing (UNOS). His appointment as President of the American Society of Histocompatibility and Immunogenetics (ASHI) in 1999 was recognition of all his contributions in the field over many years.

Finally, in 2005 he retired and he and Helena moved back to California to a lovely town house on a lagoon in Foster City. Alan and Helena had many holidays together often on ocean cruises chosen not only for their destinations but also the provision of ball room dancing after dinner. Alan who had been an excellent tennis player took it up again on a regular basis playing for the Foster City team.

He will be sadly missed by so many in the field in many parts of the world. He leaves Helena, the love of his life, and many nieces and nephews, to whom he was devoted plus innumerable friends and colleagues.

Kidney Health: Delivering Excellence – Progress report for 2017 is published

Download the full report and read a synopsis by Fiona Loud, co-author Kidney Health: Delivering Excellence, co-chair Kidney Health Partnership Board.

BTS Response to the Scottish Government’s Consultation on Legislation on Organ Donation

“The BTS has submitted a response to the Scottish government’s consultation on legislation on organ donation. The response includes results of the ‘opt out’ survey undertaking at Congress, in which 66% of respondents favour a change in legislation.

The response has been written by Antonia Cronin, as Chair of the Ethics Committee, and has agreement from the BTS executive. I am very grateful to Antonia and the committee for all their hard work.”

Lorna Marson
BTS President

Professor Sir Roy Calne pays tribute to Thomas Starzl


Dear BTS member,

As you will be aware, the pioneer of transplantation Thomas Starzl died at the weekend. 

I am very grateful to Professor Sir Roy Calne for agreeing to write an obituary for the society members, and for writing such a heartfelt piece from someone who knew Tom.

Please take time to read it as it is a fitting tribute to a remarkable man. 

An opportunity to make a difference to Renal Services at a National Level

The first ‘Getting it Right First Time’ (GIRFT) report, published by Professor Tim Briggs suggested that changes could be made to improve pathways of care, patient experience, and outcomes – with significant cost savings, and this approach now forms a key part of the roll-out of the recommendations in Lord Carter’s report (February 2016) in operational performance and productivity in acute hospitals.
As a result, Renal Services has been added to the programme roll out, and GIRFT is now looking for a skilled and effective clinical leader, who is recognised as expert by their clinical colleagues and with the endorsement of their specialty society to undertake the Renal Clinical Lead.
For further information about GIRFT, the role of Clinical Lead, and details of how to apply please visit:

Closing dates for applications: 5th February 2017

View GIRFT Clinical Leads Vacancy Advertisement.pdf

View GIRFT Editorial Feature.pdf

Call for funding for Community Initiatives


Living Donor Transplantation for Black, Asian and Minority Ethnic (BAME) Communities

NHS Blood and Transplant (NHSBT) have commissioned the National Black, Asian and Minority Ethnic Transplant Alliance to manage the delivery of a Living donor Transplantation Initiative, up until March 2018. The funding of £90,000 is in response to a recent decline in the number of living donor transplantations among BAME (Black, Asian and Minority Ethnic) communities. From 169 living donors from a BAME background in 2013/14 to 136 in 2015/16, there has been a decline of 19.5%.

The coordinated approach of NHSBT commissioned NBTA living transplant initiatives will address the inequality in donation and transplantation for BAME communities, and aim to widen the impact of effective practices that improve and save lives.

There are three key outcomes which NBTA will be required to achieve which are:

  • 40 people from BAME background seeking information or expressing an interest in living donation
  • 25 people from BAME background being assessed for living donation
  • 10 people from BAME background, after assessment, being suitable for living donation


There are four priority geographical areas and BAME communities associated with each as follows.

  1. North West London : Hindu and Jain communities
  2. West London: Sikh communities
  3. London ( targeted boroughs): African and African-Caribbean communities
  4. Leicester: Hindu and Sikh communities


Although NBTA have four priority areas, NBTA would welcome initiatives from across the UK and funding permitting will be pleased to discuss any proposals.

Following this announcement for seeking submissions, all bids should be made by 5 December 2016, using the pro-forma. The Steering Group will announce decisions on the submissions on15 December 2016 and projects can commence by early 2017. This first round of submissions may be followed by a second round in early 2017, depending on the availability of the funding.

The overall outcome for focussing on BAME living donation work is to close the gap between black and minority ethnic communities and white communities in securing transplantations at the same time as securing savings to the NHS on the costs of healthcare.  To reach these goals and the outcomes NBTA will deliver:

  • Better awareness amongst BAME communities of health inequalities and the need for donation
  • More collaborative working, and sharing of best practice amongst organisations including NHS Blood and Transplant working on donation and transplant to improve health outcomes for BAME communities
  • Incremental change in the numbers of BAME people represented on donation registers and agreeing to transplantation.
  • Collation of resources of effective interventions and materials on donation and transplant issues with BAME communities
  • Behaviour change and increased BAME and Faith Community Engagement.


Sally Johnson, Director of Organ Donation and Transplantation at NHS Blood and Transplant said:

“People from Black and Asian communities have a higher incidence of conditions such as diabetes and certain forms of hepatitis, and currently make up a third of the active kidney transplant waiting list.  Although some are able to receive a transplant from a white donor, for many the best match will come from a donor from the same ethnic background. While only 5% of all deceased organ donors currently come from black and Asian backgrounds, living donation can be the life-saving opportunity, a patient waiting for a transplant desperately needs. With increased awareness and improved information, we hope that more potential living donors will come forward and more patients will have their lives saved or transformed.”


Orin Lewis OBE, Co-chair of NBTA and Chief Executive of ACLT (African Caribbean Leukaemia Trust) said

“The NBTA applauds NHS Blood and Transplant (NHSBT) for committing its funds and trust in our members to delivering this initiative on behalf of the various UK BAME communities. This NHSBT funded initiative is a major “game changer” for BAME communities in relation to Living donor Transplantation. A successful undertaking of the 3 key outcomes will enable an acceptable positive ripple effect awareness effect from with the aforementioned BAME communities and result in more lives being saved.”


For more information on the Living Donor Transplantation Initiative and to request application pack please email Kirit Modi – Steering Group Chair on .

The National Black, Asian and Minority Ethnic Transplant Alliance (NBTA) is a forum of organisations, set up by the Department of Health, who work together on behalf of Black, Asian and Minority Ethnic (BAME) patients and communities. NBTA’s aims to address the disproportionality in stem cell, blood and organ donation through raising awareness of inequalities, promoting the importance of transplantation; with the aim of increasing the number of BAME donor registrations and consent to transplantation.

For more information on NBTA please visit

and for press interviews please contact either of the following Co-Chairs:

Mr Orin Lewis OBE on 020 3757 7700 or